FAQ

zoledronate

Known as: (1-hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonic acid, [1-Hydroxy-2-(1H-imidazol-1-yl)ethylidene]bisphosphonic Acid, NDC-Zoledronate 
The brand name for zoledronic acid, a bisphosphonic imidazol compound which inhibits osteoclastic bone resorption. Although its mechanisms of action… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

1973-2018
05010019732018

Related topics

Related topics

5 relations

Narrower (2)

CGP 42446AZOL 446
Pamidronate DisodiumZometa

Broader (1)

zoledronic acid

Related mentions per year

Related mentions per year

1973-2018
197019801990200020102020
zoledronate
zoledronic acid
Pamidronate Disodium
Zometa
CGP 42446A
ZOL 446

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2007
Highly Cited
2007
Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer.
The increasing evidence that gammadelta T cells have potent antitumor activity suggests their value in immunotherapy… (More)
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite.
Bisphosphonates are now the most widely used drugs for diseases associated with increased bone resorption, such as osteoporosis… (More)
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Calcium phosphate drug delivery system: influence of local zoledronate release on bone implant osteointegration.
Despite total hip replacement (THR) gives generally satisfactory results, the quality of outcome in young patients is markedly… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Conversions Between S , 2 , Y , h , ABCD , and T Parameters which are Valid for Complex Source and Load Impedances
  • Dean A. Frickey
  • 2004
OST microwave textbooks these days seem to provide M a table of the conversion between the various 2-port parameters. These 2… (More)
  • table I
  • table VI
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion.
BACKGROUND Treatment with zoledronic acid (Zol) was compared with a dose of 90 mg of pamidronate (Pam) in breast carcinoma (BC… (More)
Is this relevant?
Highly Cited
2003
Highly Cited
2003
Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic.
 
Is this relevant?
Highly Cited
2003
Highly Cited
2003
Toxic acute tubular necrosis following treatment with zoledronate (Zometa).
BACKGROUND Renal failure and toxic acute tubular necrosis (ATN) may be seen following exposure to a variety of therapeutic agents… (More)
Is this relevant?
Highly Cited
2001
Highly Cited
2001
Bisphosphonate treatment inhibits the growth of prostate cancer cells.
The presence of skeletal metastases in patients suffering from cancer leads to a variety of clinical complications… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2000
Highly Cited
2000
Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases.
The molecular mechanisms by which tumor cells metastasize to bone are likely to involve invasion, cell adhesion to bone, and the… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2000
Highly Cited
2000
Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts.
Bisphosphonates are widely used clinically to treat bone diseases in which bone resorption is in excess. However, the mechanism… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 5
  • figure 4
Is this relevant?